You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
Colorcon
Dow
Merck

Last Updated: May 17, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DARZALEX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for DARZALEX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01592370 Safety Study of Nivolumab by Itself or in Combination in Patients With Lymphoma or Multiple Myeloma Recruiting Bristol-Myers Squibb Phase 1 2012-06-01 The purpose of this study is to determine the side effects of treatment with Nivolumab by itself or in combination in patients with relapsed/ refractory lymphoma or multiple myeloma.
NCT02841033 Daratumumab for the Treatment of Patients With AL Amyloidosis Not yet recruiting Janssen Pharmaceuticals Phase 1/Phase 2 2016-10-01 Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month. Study treatment may continue until disease progression, unacceptable toxicity, or decision to withdraw from the trial. Disease evaluations will be performed every three months until disease progression.
NCT02841033 Daratumumab for the Treatment of Patients With AL Amyloidosis Not yet recruiting Vaishali Sanchorawala Phase 1/Phase 2 2016-10-01 Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month. Study treatment may continue until disease progression, unacceptable toxicity, or decision to withdraw from the trial. Disease evaluations will be performed every three months until disease progression.
NCT02977494 Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Not yet recruiting University Hospital Tuebingen Phase 2 2016-12-01 Myeloma patients with renal impairment need a rapid and effective reduction of tumor burden to enable renal recovery, which is correlated with prognosis of the patients. However, effective combination regimens are often hampered by necessary dose reductions or increased toxicity in renally impaired patients. The well known positive effects on renal impairment by Bortezomib combined with Daratumumab, which, as all monoclonal Antibody, is not renally excreted or metabolized and as so far known should not add significant toxicity but efficacy, makes the proposed combination of Daratumumab, Bortezomib and Dexamethasone highly attractive for renally impaired MM patients. In the current clinical trials with Daratumumab patients with renal function impairment (GFR ≤ 20 ml/min) were so far excluded. Consequently questions about efficacy, safety and pharmacokinetics of Daratumumab in combination with Bortezomib and Dexamethasone in patients with relapsed and refractory MM and severe renal impairment are still unanswered. This trial will answer these questions for a patient group, who has still an unmet need for novel and effective treatment options
NCT03004287 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Not yet recruiting Janssen, LP Phase 2 2017-06-01 This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
NCT03004287 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Not yet recruiting University of Arkansas Phase 2 2017-06-01 This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
NCT03012880 Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma Not yet recruiting National Cancer Institute (NCI) Phase 2 2017-03-01 This phase II trial studies how well ixazomib citrate, lenalidomide, dexamethasone, and daratumumab work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as daratumumab, may block cancer growth in different ways by targeting certain cells. Giving ixazomib citrate, lenalidomide, dexamethasone, and daratumumab may work better in treating patients with newly diagnosed multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DARZALEX

Condition Name

Condition Name for DARZALEX
Intervention Trials
Multiple Myeloma 22
Recurrent Plasma Cell Myeloma 7
Plasma Cell Myeloma 7
Refractory Plasma Cell Myeloma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DARZALEX
Intervention Trials
Neoplasms, Plasma Cell 41
Multiple Myeloma 41
Lymphoma 6
Leukemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DARZALEX

Trials by Country

Trials by Country for DARZALEX
Location Trials
United States 104
Canada 9
France 3
Poland 3
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DARZALEX
Location Trials
Minnesota 11
California 10
Massachusetts 8
Florida 7
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DARZALEX

Clinical Trial Phase

Clinical Trial Phase for DARZALEX
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 39
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DARZALEX
Clinical Trial Phase Trials
Not yet recruiting 44
Recruiting 13
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DARZALEX

Sponsor Name

Sponsor Name for DARZALEX
Sponsor Trials
National Cancer Institute (NCI) 14
Janssen, LP 8
Janssen Scientific Affairs, LLC 6
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DARZALEX
Sponsor Trials
Other 57
Industry 44
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Harvard Business School
McKesson
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.